Department of Ophthalmology, The First Hospital of China Medical University, Shenyang, China.
Retina. 2012 Jun;32(6):1106-13. doi: 10.1097/IAE.0b013e318242b9da.
To evaluate the efficacy and safety of intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy.
Twelve eyes of 12 patients with subfoveal or juxtafoveal choroidal neovascularization secondary to punctate inner choroidopathy received intravitreal bevacizumab injection (1.25 mg) in this prospective case series. Injection was repeated if persistent or recurrent activity of choroidal neovascularization was indicated by optical coherence tomography or fundus fluorescein angiography at 1-month intervals. Visual, clinical, angiographic, and anatomical changes were observed over a 12-month follow-up period.
After 12 months of follow-up, mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.49 (20/62 in Snellen equivalent) at baseline to 0.23 (20/34 in Snellen equivalent; P < 0.001). Mean central retinal thickness determined by optical coherence tomography decreased from 333 μm to 241 μm (P < 0.001). All eyes (100%) had stable or improved vision, and 9 eyes (75%) showed an improvement of ≥ 2 lines. All lesions converted to the cicatricial phase after 12 months of follow-up. No drug-related systemic or ocular side effects were observed.
Intravitreal bevacizumab is well tolerated and improves best-corrected visual acuity in choroidal neovascularization secondary to punctate inner choroidopathy over a 12-month period.
评估玻璃体内注射贝伐单抗作为特发性脉络膜新生血管（PCV）的初始治疗的有效性和安全性。
本前瞻性病例系列研究共纳入 12 例 12 眼特发性脉络膜新生血管患者，均接受玻璃体内注射贝伐单抗（1.25mg）治疗。如果光学相干断层扫描或眼底荧光血管造影在 1 个月时显示脉络膜新生血管持续或复发，则重复注射。观察 12 个月的随访期间的视力、临床、血管造影和解剖变化。
12 个月随访后，最佳矫正视力的最小分辨角对数均值从基线时的 0.49（20/62 视力等价 Snellen）提高到 0.23（20/34 视力等价 Snellen；P<0.001）。光学相干断层扫描测量的中心视网膜厚度均值从 333μm 降低至 241μm（P<0.001）。所有眼（100%）视力稳定或改善，9 眼（75%）视力提高≥2 行。所有病变在 12 个月随访后均转为瘢痕期。未观察到与药物相关的全身或眼部不良反应。
玻璃体内注射贝伐单抗治疗特发性脉络膜新生血管是安全且耐受良好的，可在 12 个月内改善视力。
